2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3786 Efficacy and safety of different doses of pegylated interferon alpha-2b in high-risk Essential Thrombocythemia Resistant or intolerant to hydroxyurea: A Multicenter Randomized Phase II study

Rongfeng Fu, Yanhong Tong2, Jian Huang3, Minghui Duan, MD4, Tiejun Gong5, Yong Wu6, Na Xu7, Wen Wu8, Hu Zhou, MD9, Hongxia Shi10, Renchi Yang, MD11, Yalin Yin12, Ruoyi He13, Ying Zheng14, Jianbo Gu15, Lei Zhang, MD16
1 Department of Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2 Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China
3 Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China
4 Department of Hematology, Peking Union Medical College Hospital, Beijing, China
5 The Institute of Hematology and Oncology, The First Hospital of Harbin, Harbin, China
6 Department of Hematology, Fujian Medical University union hospital, Fuzhou, Fujian, China, Fuzhou, China
7 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
8 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
10 Peking University People's Hospital, Beijing, China
11 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
12 Xiamen Amoytop Biotech Co., Ltd., Xiamen, China
13 Xiamen Amoytop Biotech Co., Ltd., Xiamen, China
14 Xiamen Amoytop Biotech Co., Ltd., Xiamen, China
15 Xiamen Amoytop Biotech Co., Ltd., Xiamen, China
16 Department of Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Background:

Approximately 20–25% of patients with high-risk essential thrombocythemia (ET) develop resistance or intolerance to hydroxyurea (HU). Pegylated interferon alfa-2b (PEG IFNα-2b) is a guideline-recommended treatment for myeloproliferative neoplasms(MPNs); however, it has not yet been approved for the treatment of ET in China, and its optimal therapeutic dose remains undefined. This study aimed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of two dose levels of PEG IFNα-2b (135 μg/week and 180 μg/week) in HU-resistant/intolerant ET patients.

Methods:

This multicenter, randomized (1:2), open-label phase II study (ChiCTR2400088120) enrolled patients with HU-resistant or HU-intolerant high-risk ET. Patients were randomized to receive subcutaneous PEG IFNα-2b(Pegbing®, Xiamen Amoytop Biotech Co., Ltd.) at 135 μg or 180 μg weekly for 48 weeks. The primary endpoint was PK parameters and exposure–response relationships. Secondary endpoints included safety and efficacy outcomes, including complete hematologic response (CHR) and complete response (CR). This report presents the second interim analysis at 48 weeks.

Results:

28 patients from 9 sites in China were randomized to the PEG IFNα-2b 135 μg group (n=8) or 180 μg group (n=20), with well-balanced baseline characteristics. At week 48, 21 patients (75.0%) completed the study, while 7 discontinued early (1 [12.5%] in the 135 μg group vs. 6 [30.0%] in the 180 μg group) due to patient withdrawal (10.7%), SAEs (7.1%), major thrombosis (3.6%), or investigator decision (3.6%). PK analysis showed dose-dependent increases in Cmax and AUC0–last, steady state was achieved by week 8.

At Week 48, CHR rates were identical in the 135 μg and 180 μg groups (57.1% [4/7] vs. 57.1% [8/14], P=1.00), as were CR rates (42.9% [3/7] vs. 42.9% [6/14], P=1.00). Both groups showed sustained reductions in platelet and white blood cell (WBC) counts. The 180 μg group exhibited a stronger trend in blood count reduction. At 48 weeks, the median reductions from baseline in PLT were −238.0 vs. −313.5 ×109/L(P=0.73), and in WBC were -1.95 vs. -3.16 ×109/L (P=0.41). Meanwhile, 100% of patients in both groups achieved WBC≤10×109/L, whereas the proportions of patients achieving PLT ≤400×109/L were 57.1% vs. 71.4% (P=0.638). A reduction in JAK2 V617F variant allele frequency (VAF) was observed in 63.2% (12/19) of evaluable patients, including 66.7% (4/6) in the 135 μg group and 61.5% (8/13) in the 180 μg group (P=1.00). One patient (16.7%) in the 180 μg group achieved bone marrow histologic remission. Spleen length and EQ-5D-3L scores remained stable in both groups.

Safety analysis showed 100% TEAE/TRAE rates in both groups (commonly hepatic dysfunction, cytopenias, flu-like symptoms). During the first 2 weeks after treatment initiation, both the incidence and severity of fever were higher in the 180 μg group than in the 135 μg group. Grade ≥3 TRAEs occurred in 75.0% and 50.0% of patients, respectively, while serious adverse events (SAEs) were reported in 25.0% and 20.0% of patients. One thrombotic event occurred in the 180 μg group; no bleeding or disease progression was observed.

Summary/Conclusion:

PEG IFNα-2b demonstrated significant and durable hematologic while effectively reducing molecular mutation burden over 48 weeks in high-risk ET patients resistant or intolerant to HU. The 135 μg and 180 μg groups achieved equivalent CHR and CR rates at 48 weeks. Given its improved early tolerability profile, particularly regarding the mitigation of early-onset fever, suggesting that 135 μg may represent a more favorable starting dose for this patient population by reducing the risk of treatment interruption due to early adverse events.

Lei Zhang, MD: No relevant conflicts of interest to declare.